Pharos IBio Co (XKRX:388870) Beginning Cash Position : ₩4,629.13 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Pharos IBio Co Beginning Cash Position?

Pharos IBio Co's Beginning Cash Position for the quarter that ended in Dec. 2024 was ₩4,629.13 Mil.

Pharos IBio Co's quarterly Beginning Cash Position declined from Jun. 2024 (₩10,752.80 Mil) to Sep. 2024 (₩6,617.58 Mil) and declined from Sep. 2024 (₩6,617.58 Mil) to Dec. 2024 (₩4,629.13 Mil).

Pharos IBio Co's annual Beginning Cash Position declined from Dec. 2022 (₩18,812.29 Mil) to Dec. 2023 (₩3,811.91 Mil) but then increased from Dec. 2023 (₩3,811.91 Mil) to Dec. 2024 (₩15,587.84 Mil).

Pharos IBio Co Beginning Cash Position Historical Data

The historical data trend for Pharos IBio Co's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharos IBio Co Beginning Cash Position Chart

Pharos IBio Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Beginning Cash Position

Get a 7-Day Free Trial

3,602.07

9,807.25

18,812.29

3,811.91

15,587.84

Pharos IBio Co Quarterly Data
	Dec19	Dec20	Dec21	Mar22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Beginning Cash Position	Get a 7-Day Free Trial									11,704.56	15,587.84	10,752.80	6,617.58	4,629.13

Pharos IBio Co Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Pharos IBio Co Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Pharos IBio Co's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharos IBio Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharos IBio Co Ltd (XKRX:388870) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

427beon-gil, Dongan-gu, 1407 and 1408, 38, Heungan-daero, Seongji Star With, Gyeonggi-do, Gwanyang-dong, Anyang-si, KOR

Website

https://www.pharosibio.com

Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.

Pharos IBio Co Headlines

No Headlines